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Rationale: Although warfarin is an established anticoagulation therapy for prevention of 
ischemic strokes in patients with atrial fibrillation, studies reporting INR values with correlation 
to warfarin efficacy and safety outcomes in patients on hemodialysis with atrial fibrillation are 
scarce. The purpose of this study was provide additional information to aid in optimizing future 
clinical anticoagulation decisions for patients with atrial fibrillation on hemodialysis. 
Methods: A retrospective cohort study was conducted from April 2011 to January 2019 at a 
regional kidney dialysis centre in southwestern Ontario, Canada. The primary objective of this 
study was to correlate achieved INR measurements with the efficacy and safety of warfarin 
anticoagulation. 
Results: A total of286 patients were reviewed and 25 patients were included. No ischemic 
strokes were reported and six bleeding episodes occurred. The mean INR of the 25 patients was 
2.4 (SD±0.47) with an average follow up of336 days. Using a Cox Proportional Hazards Model, 
univariate correlations between risk of bleeding and baseline characteristics were examined and 
no statistically significant correlations were found. 
Conclusion: Patients on hemodialysis with atrial fibrillation may have a higher bleeding rate 
while on warfarin despite having therapeutic IN Rs. This may be attributed to the small sample 
size, duration of observation and factors such as intra-dialysis heparin use and uremic platelet 
dysfunction. Therefore, initiating warfarin for primary prevention in this patient population 
requires a careful assessment of bleeding risk factors. Further studies are warranted. 
INTRODUCTION 
In patients with end stage chronic kidney 
disease (defined as an eGFR <15 
mL/min/1.73 m2) requiring hemodialysis 
with the additional diagnosis of atrial 
fibrillation, the risk-to-benefit ofusing 
warfarin for primary prevention of adverse 
events due to atrial fibrillation is unclear. 
Patients on hemodialysis with atrial 
fibrillation pose a paradox to clinicians 
because concurrently they are at a high risk 
of a thrombotic event as well as a bleeding 
event.1 Despite the higher risk for 
cardioembolic strokes due to atrial 
fibrillation, chronic kidney disease is 
associated with a prothrombotic state due to 
abnormalities in clotting factors and an 
underlying inflammatory state placing 
patients at up to ten times higher risk of 
adverse clotting events. Furthermore, 
patients with end stage renal disease are at a 
higher risk of bleeding events due to 
impairment in renal clearance ofuric acid 
which leads to platelet dysfunction.1 •2·3 
CHADS2 and CHA2DS2-V ASc risk 
assessment scores are used to stratify the 
risk for stroke in patients with atrial 
fibrillation.2 However, patients with chronic 
kidney disease were underrepresented in 
studies that validated the CHADS2 and 
CHA2DS2-VASc risk tools and as such are 
not currently included in the risk scores' 
criteria. This makes assessment of stroke 
risk difficult in patients with atrial 
fibrillation and hemodialysis. 1 Bleeding 
rates in this patient group are difficult to 
ascertain from current literature as studies 
may use various definitions for bleeding 
events. At present, the study reported rate of 
bleeding events for patients on hemodialysis 
with fibrillation varies from 2.5-54% per 
year.1,3 
The current Canadian and American 
clinical practice guidelines provide different 
recommendations with respect to this 
specific patient population. The 2012 
Canadian Cardiovascular Society Atrial 
Fibrillation Guidelines do not routinely 
recommend anticoagulation with warfarin in 
patients with atrial fibrillation and 
hemodialysis due to a lack of evidence. In 
contrast, the 2014 American Heart 
Association ! American College of 
Cardiology Guidelines for Atrial Fibrillation 
recommend warfarin anticoagulation for 
patients with a CHA1DS2-VASc score of 2 
or greater and who have end-stage chronic 
kidney disease or are on hemodialysis. 
However, the data for this recommendation 
has been derived from a single study.2·4 
Evidence evaluating the safety and 
efficacy of warfarin in this specific patient 
population shows conflicting results. Of 
greater importance, International 
Normalized Ratio (INR) data which is used 
to assess warfarin degree of anticoagulation 
has not been provided or accurately 
monitored in studies published to date. 
Current studies have not correlated 
outcomes with INR targets and CHADS2 
scores.5 Further, information from the 
International Dialysis Outcomes and 
Practice Patterns Study (DOPPS) cohort 
study showed oral anticoagulation in 
patients with hemodialysis increased major 
bleeding events, all cause and cardiovascular 
mortality. However, DOPPS highlighted as 
a significant limitation the lack of INR 
measurements, as well as a lack of assessing 
warfarin adherence since patient information 
was collected on an outpatient basis.6 
At present time there is a conflicting 
body of evidence regarding warfarin therapy 
for primary prevention in patients with atrial 
fibrillation on hemodialysis . The degree of 
risk and/or benefit of warfarin in this patient 
population cannot be accurately determined 
without assessing how efficacy and safety 
clinical outcomes relate to reaching INR 
targets. This study will be a pilot study to 
collect INR data and identify the correlation 
between the achieved INR targets and risk 
and benefit associated with warfarin use in 
this patient population. The ultimate goal of 
this study is to provide additional 
information to aid in optimizing future 
clinical anticoagulation decisions for 




Upon Research Ethics Board 
clearance, a retrospective chart review was 
conducted at a regional kidney dialysis 
centre in southwestern Ontario, Canada 
between Apri I 1, 201 1 and January 31, 2019. 
This specific time frame was selected to 
incorporate all available warfarin dosing 
records for patients that met the inclusion 
criteria. Patients were included in the study 
if they met all of the following: (1) patient at 
least 18 years old, (2) patient on 
hemodialysis, (3) patient with a diagnosis of 
atrial fibrillation, (4) received warfarin for 
primary prevention of ischemic stroke. 
Patients were excluded if they: (I) were 
pregnant, (2) under the age of 18 years old, 
(3) had concurrent venous 
thromboembolism, (4) received concurrent 
chemotherapy, (5) had a history of transient 
ischemic attack and/or cerebrovascular 
accident, (6) had valvular atrial fibrillation 
with an INR target of2.5 to 3.5, (7) received 
chronic NSA!Ds and/or corticosteroids 
and/or anti platelet agents defined as use of 
one of the above agents for more than 30 
days, (8) received warfarin for less than 
seven days, (9) had other concurrent 
indications for warfarin use, ( 10) were on 
peritoneal dialysis. 
Definitions 
The patient data was collected from 
individual electronic records and maintained 
in a computerized spreadsheet. Pharmacists 
monitored INR values minimum weekly and 
more frequently if required then adjusted 
warfarin dose requirements accordingly. 
Information collected by the pharmacists 
adjusting the warfarin dosage included INR 
values, hemoglobin, platelets, serum 
creatinine, pertaining drug interactions, 
changes in diet and other relevant 
information such as upcoming procedures. 
The following outcomes were tracked 
for each patient from the initiation of 
warfarin to either discontinuation of 
warfarin, death or end of study period ie. 
January 31, 2019: major bleeding events, 
minor bleeding events and ischemic strokes. 
Bleeding events were defined in accordance 
to the International Society on Thrombosis 
and Haemostasis. 7·8 
Major bleeding was defined as: (I) fatal 
bleeding; and/or (2) symptomatic bleeding 
in a critical area or organ, such as 
intracranial, intraspinal, intraocular, 
retroperitoneal, intra-articular, pericardia[, or 
intramuscular with compartment syndrome; 
and/or (3) bleeding causing a fall in 
hemoglobin level of 20 g/L or more or 
leading to transfusion of two or more units 
of whole blood or red cells. 7 Minor bleeding 
was defined as: any sign or symptom of 
hemorrhage (e.g., more bleeding than would 
be expected for a clinical circumstance 
' 
including bleeding found by imaging alone) 
that would not fit the criteria for the 
definition of major bleeding but does meet 
at least one of the following criteria: (1) 
requiring medical intervention by a 
healthcare professional, (2) leading to 
hospitalization or increased level of care, (3) 
prompting a face to face evaluation. 8 
Ischemic strokes were diagnosed based on 
documentation on CT scan. 
The primary endpoint focused on 
investigating the correlation between 
achieved INR measurements at this 
institution with the efficacy and safety of 
warfarin anticoagulation to prevent 
thromboembolism due to atrial fibrillation in 
a local hemodialysis population. 
Data Analysis 
Data were analyzed using a repeated 
measures AN OVA statistical method. Basic 
descriptive statistics were performed to 
describe the sample characteristics. A Cox 
Proportional Hazards Model was performed 
to examine the univariate correlations 
between the risk of bleeding and the 
patients' baseline characteristics. 
RESULTS 
Sample Characteristics 
A total of 286 charts were reviewed 
and 25 patients met the inclusion criteria. 
Table I displays the patients· baseline 
characteristics. The results indicate the 
average age in the sample was 77 .4 years 
old with a SD±7 years. Females comprised 
48% (n=I 2) of the sample. The following 
CHADS 2 risk factors were identified for all 
included patients: congestive heart failure, 
hypertension, and diabetes. In addition, the 
use of ACEi, ARB and P-Blocker 
medications were identified for each patient 
because these agents can impact long term 
mortality and blood pressure control. 
INR Values and Outcome Analysis 
The mean follow up time from warfarin 
initiation was 336 (SD±40 I) days with a 
minimum of 19 days and a maximum of 
1688 days. Figure I illustrates the 
distribution of the mean INR measurements 
for the 25 patients. Over the follow up 
period from warfarin initiation to the last 
documented INR found in the patient's 
chart, the average INR for the 25 patients 
was 2.4 (SD±0.47) with a minimum value of 
1.7 and a maximum value of 4.1. The 
Kaplan Mayer Survival Curve in Figure 2 
illustrates the median time to bleeding was 
estimated to be 1461 days (4 years) with a 
lower bound 95% confidence interval of 812 
days (2.2 years). Given the limitations in the 
data, an upper bound of the confidence 
interval is not estimable. 
No ischemic strokes occurred. A total 
of six bleeding episodes were identified of 
which five episodes were minor events and 
one episode was classified as a major event. 
Table 2 displays the descriptions of the 
bleeding events and the INRs at which they 
occurred. The major bleed event identified 
was a retroperitoneal bleed which occurred 
at an INR of2.8. Using a Cox Proportional 
Hazards Model, univariate correlations 
between risk of bleeding and baseline 
characteristics were examined and no 
statistically significant co1Telations were 
found. 
DISCUSSION 
The findings reported here suggest 
that use of warfarin for atrial fibrillation 
patients on hemodialysis may lead to a 
Table 1. Baseline Characteristics 
Average Age (years) 
Female 
Congestive Heart Failure 
Hypertension 
Diabetes 
Use of ACEi/ ARB 
Use of ~-Blocker 
CHADS2 score of 1 
CHADS2 score of 2 
CHADS2 score of3 
CHADS 2 score of~4 
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Table 2. Descriptions of Bleeding Events 
EVENT NUMBER PATIENT SITE OF BLEED 
Retroperitoneal bleed 
2 Hemoptysis 
3 Gingival bleeding 
4 2 Melena 
5 3 Hematuria 
6 4 Hematemesis 
VALUE(%) 
12 
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Figure 2. Kaplan Meier Survival Curve 
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higher incidence of bleeding events despite 
therapeutic IN Rs without a decrease in risk 
of ischemic events. Patients had no ischemic 
strokes despite most patients having a higher 
CHADS2 score of four. However, patients 
bled despite an average therapeutic INR of 
2.4. This is an important finding as 
published data is limited with regards to 
INR reporting in relation to outcomes. 
The findings from this study support 
previous observational studies that have 
reported a higher rate of bleeding events in 
this patient population. For instance, the 
systematic review and meta-analysis 
performed by Nochaiwong et al showed no 
statistically significant difference in all-
cause mortality and thromboembolism 
outcomes for patients on warfarin compared 
to those not on it. Furthermore, they showed 
warfarin use was associated with a 
statistically higher risk of bleeding events. 
However, risk of hemorrhagic stroke was 
not increased . The studies included in this 
meta-analysis did not provide any data on 
outcome correlation with CHADS 2 scores. 
Of greater importance , INR data which is 
used to assess warfarin degree of 
anticoagulation was not provided by 
Nochaiwong et al.5 In a similar systematic 
review of stroke and bleeding outcomes of 
warfarin use in atrial fibrillation patients on 
hemodialysis, Tsai et al demonstrated 
warfarin was not associated with a decrease 
in rates of stroke at an expense of increased 
rates of bleeding. However , the data 
included were observational cohort studies 
and most did not report INR measurements. 9 
Further evidence from DOPPS 
showed oral anticoagulation in patients with 
hemodialysis increased major bleeding 
events, all cause and cardiovascular 
mortality. In addition to previous evidence , 
the DO PPS study was able to report 
moderately increased rates of bleeding and 
stroke events in patients on hemodialysis 
and using an oral anticoagulant for atrial 
fibrillation with high CHADS2 score 
(defined as ~2), without a prior history of 
gastrointestinal bleed. However, DOPPS 
highlighted as a significant limitation the 
lack of INR measurements, as well as a lack 
of assessing warfarin adherence since 
patient information was collected on an 
outpatient basis .6 
The rates of bleeding in patients with 
atrial fibrillation on hemodialysis may be 
higher due to other potential factors such as 
heparin use intra-dialysis and 
pathophysiological changes such as uremic 
platelet dysfunction. 10 There are no 
randomized controlled trials to show that 
intradialytic use of heparin increases the 
bleeding risk in this patient population. The 
data thus far is limited to case reports 
showing an association rather than causation 
between heparin intradialysis and bleeding 
events. 11 
Of more importance it has been 
shown that there is platelet dysfunction in 
patients with end stage renal disease caused 
primarily by uremia . In patients with renal 
failure there is disturbance of the a-granules 
which contain coagulation factors V and 
XIII. as well as von Willebrand Factor 
(vWF) leading to higher bleeding propensity 
due to inability of platelets to bind to each 
other and the blood vessel wall. These 
patients also have impaired synthesis and 
release of thromboxane A2 resulting in 
reduced aggregation of platelets. A higher 
degree of oxidative stress and inflammation 
can also decrease platelet function in this 
patient population. Arguably. these 
abnormalities in platelet function due to 
uremia toxin build up can be reversed\\ ith 
hemodial:rsis as the uremia is cleared. 10 
Therefore . irrespective of other 
potential confounding factors. use of 
\\arfarin in patients with atrial fibrillation 
and hemodialysis appears to pose an 
increased risk of bleeding without possibly a 
decreasing rate of ischemic strokes. 
LIMITATIONS 
The study has several limitations. 
First, this was a retrospective review and 
therefore outcome reporting was heavily 
reliant on complete documentation. No 
control group could be identified because 
patients with atrial fibrillation on 
hemodialysis that are not on warfarin were 
not actively tracked by pharmacists . 
Finally, the study may be underpowered due 
to the small sample size. Also, the study 
duration may not have been sufficiently long 
to capture all possible events. All these 
factors may have introduced bias in the 
interpretation of the study results. 
CONCLUSION 
Patients on hemodialysis with atrial 
fibrillation may have a higher bleeding rate 
while on warfarin despite having therapeutic 
INRs. This may be attributed to the small 
sample size, duration of observation and 
factors such as intra-dialysis heparin use and 
uremic platelet dysfunction. Therefore, 
initiating warfarin for primary prevention in 
this patient population requires a careful 
assessment of bleeding risk factors. Further 
studies are warranted. 
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